Drugs / delta-9-tetrahydrocannabinol (delta-THC)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01608217 Comparator | Jun 2012 → Jun 2014 | Alzheimer disease, disruptive behavior disorder, vascular dementia | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | delta-9-tetrahydrocannabinol (delta-THC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01608217 ↗ |
| Known as | THC | “The included studies tested natural delta-9-tetrahydrocannabinol (THC) (Namisol) and two types of synthetic THC analogue (dronabinol and nabilone).” PMID 34532852 ↗ Sep 2021 |